Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Research & Development (2022 - 2025)

Historic Research & Development for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • PAVmed's Research & Development changed N/A to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2024, which is 5844.77% down from last year.
  • As of Q3 2025, PAVmed's Research & Development stood at $1.1 million.
  • In the past 5 years, PAVmed's Research & Development ranged from a high of $6.7 million in Q2 2022 and a low of $787000.0 during Q1 2025
  • Over the past 4 years, PAVmed's median Research & Development value was $3.3 million (recorded in 2023), while the average stood at $3.3 million.
  • In the last 5 years, PAVmed's Research & Development plummeted by 3172.62% in 2023 and then crashed by 7755.22% in 2024.
  • Over the past 4 years, PAVmed's Research & Development (Quarter) stood at $6.7 million in 2022, then crashed by 46.13% to $3.6 million in 2023, then plummeted by 77.55% to $807000.0 in 2024, then skyrocketed by 34.82% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $790000.0 for Q2 2025, and $787000.0 during Q1 2025.